Clinical and prognostic analysis of diffuse large B-Cell lymphoma patients with varying levels of HDAC3
YE Jun-ling
GUO Xin-jian
GOU Xiao-dan
ZHENG Xiao-ying
GONG Xue
HAN Jing-qi
Abstract：Objective This study aimed to investigate the correlation between different levels of histone deacetylase 3(HDAC3)and the clinical pathological characteristics and prognosis in patients with Diffuse Large B-Cell Lymphoma(DLBCL),and to assess the potential of HDAC3 as a prognostic biomarker.Methods The study enrolled 86 patients with DLBCL,employed immunohistochemical staining to detect HDAC3 protein expression,and utilized receiver operating characteristic(ROC)curve and logistic regression analysis to assess its association with clinical pathological features and prognosis.Results In DLBCL patients,47 cases(54.65%)had poor prognosis,and 39 cases(45.35%)had good prognosis.The expression level of HDAC3 in tumor tissue was significantly higher than that in normal tissue(P＜0.05),with a cutoff value of 4.50.High-level HDAC3 expression(≥5 points)is an independent predictor of poor prognosis(P＜0.05).Additionally,advanced Ann Arbor stage,high international prognostic index(IPI),and Eastern Cooperative Oncology Group Performance Status scale(ECOG PS)scores are also independent predictors of poor prognosis(P＜0.05).Conclusion Elevated HDAC3 levels were significantly linked to unfavorable outcomes in patients with DLBCL,suggesting that HDAC3 could potentially act as a biomarker for evaluating prognosis in DLBCL.
Keywords：Diffuse large B-cell lymphomaHistone deacetylase 3Pathological characteristicsPrognosticBiomarker
Publication Date：2025-06-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 659-665 )